Paxman expands beyond scalp cooling with neuropathy system launch
Paxman has launched its Paxman Neuropathy System in Europe, a cryocompression device aimed at reducing chemotherapy-induced peripheral neuropathy. The rollout follows published clinical data and marks the company’s first major move beyond scalp cooling for chemotherapy-related hair loss.
Why it matters: - Chemotherapy-induced peripheral neuropathy, or CIPN, is a major unmet need in cancer care. - CIPN can cause numbness, pain, tingling and loss of sensation in the hands and feet. - The condition can affect daily activities, quality of life and treatment adherence. - A preventive standard of care is not yet established. - Paxman’s launch expands the company beyond scalp cooling into another cancer treatment side effect with long-term impact.
What happened: - Paxman announced the commercial launch of the Paxman Neuropathy System on November 5, 2026. - The device uses cryocompression technology to help reduce the risk and severity of CIPN. - The launch is Paxman’s first major expansion beyond scalp cooling for chemotherapy-related hair loss. - The company is rolling out the system in the United Kingdom, France, Germany, the Netherlands, Spain and Italy after recent regulatory approvals. - Pilot programs are already underway in the United Kingdom.
The details: - Paxman said the Neuropathy System builds on more than 25 years of leadership in scalp cooling. - The company’s position in scalp cooling was strengthened by its acquisition of Dignitana in 2025. - The new system is designed to address a treatment side effect that can lead to chemotherapy dose reductions, delays or discontinuation. - CIPN affects millions of cancer patients worldwide each year. - Symptoms can persist long after treatment ends. - Clinical trial data published in JCO Oncology Advances came from a prospective multicenter phase I/II study in patients receiving taxane-based chemotherapy. - The study found the device was safe, well tolerated and linked to low rates of CIPN. - Among 146 evaluable patients, none developed severe neuropathy. - Patient-reported sensory symptoms remained low over follow-up. - A separate review in Therapeutic Advances in Medical Oncology examined the causes, impact and prevention strategies for CIPN. - The review highlighted cryotherapy and cryocompression as among the most promising emerging interventions.
Between the lines: - The launch gives Paxman a second product category in oncology supportive care. - The timing of the rollout alongside two publications helps frame the system as evidence-backed rather than purely commercial. - The company is positioning cryocompression as a practical way to help more patients stay on prescribed chemotherapy regimens. - Further validation is still being built through ongoing studies, including the randomized SWOG S2205 ICE COMPRESS trial in the United States and another active trial at Dana-Farber Cancer Institute.
What's next: - Paxman expects to expand the technology to additional European centers in the coming months. - Ongoing clinical research will continue to test the system’s role in preventing CIPN. - Results from the U.S. randomized trial and the Dana-Farber study may shape broader adoption if they reinforce the early findings.
The bottom line: - Paxman is moving from scalp cooling into a new oncology market with a device backed by early clinical data and a growing evidence base.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Madrid Wire
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.